What question did this study set out to answer?

The aim is to identify DNA methylation subtypes in resistant tumors to better inform clinical decisions.

February 2, 2026Clinical EpigeneticsOpen Access

Characterization and clinical implications of CpG island methylator phenotypes of resistant tumors

View Full Paper

Ask AI

Bookmark

The aim is to identify DNA methylation subtypes in resistant tumors to better inform clinical decisions.
Characterization of methylation patterns in resistant tumor samples
Analysis of clinical data for prognosis and therapy selection
Stratification of tumors based on identified methylation subtypes
Identification of distinct CpG island methylator phenotypes
Enhanced ability to predict treatment responses
Potential for improved patient stratification and personalized therapy approaches

Uncovers DNA methylation subtypes, influencing prognosis and therapy selection in resistant tumors, suggesting improved treatment strategies.

This study uncovers DNA methylation subtypes within resistant tumors, enabling more precise stratification to inform prognosis and therapy selection.

No takes yet. Share an insight, caveat, or question.

Hou et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Uncovers DNA methylation subtypes, influencing prognosis and therapy selection in resistant tumors, suggesting improved treatment strategies.

This study uncovers DNA methylation subtypes within resistant tumors, enabling more precise stratification to inform prognosis and therapy selection.